Comparative Pharmacology
Head-to-head clinical analysis: KETOZOLE versus MICONAZOLE NITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOZOLE versus MICONAZOLE NITRATE.
KETOZOLE vs MICONAZOLE NITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketoconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This leads to increased membrane permeability and cell death.
Inhibits fungal CYP450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
200 mg orally once daily with food.
Topical: Apply twice daily for 2-4 weeks. Vaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 1200 mg suppository as a single dose. Oral (buccal): 50 mg once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5–3.5 hours). Clinically, duration of antifungal effect extends beyond plasma half-life due to persistent tissue levels.
Terminal elimination half-life is approximately 24 hours (range 20-40 hours) following intravenous administration. This extended half-life supports twice-daily dosing for systemic infections.
Primarily hepatic metabolism; renal excretion of unchanged drug <1%. Biliary/fecal excretion accounts for ~20-35% of metabolites.
Miconazole is primarily metabolized in the liver, with less than 1% of an intravenous dose excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 50% of the dose as metabolites. Renal elimination of metabolites is minimal.
Category C
Category A/B
Antifungal
Antifungal